8-K: AbbVie Updates 2024 Earnings Guidance to Include $164 Million IPR&D Expense

AbbVie has revised its 2024 earnings guidance to incorporate a $164 million expense related to acquired IPR&D and milestones, impacting both GAAP and adjusted non-GAAP diluted earnings per share.

Summary

• AbbVie has announced that its first quarter 2024 results will include a $164 million pre-tax expense for acquired IPR&D and milestones.
• This expense will negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.08.
• The company's full-year 2024 adjusted diluted earnings per share guidance, including this expense, is now $10.97 $11.17.
• The first quarter 2024 adjusted diluted earnings per share guidance, including the expense, is $2.18 $2.22.
• The company does not forecast future acquired IPR&D and milestone expenses due to the uncertainty of these transactions.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the downward revision of earnings guidance caused by the IPR&D expense. While these expenses are common, they still negatively impact the company's short-term financial outlook.

Negatives

• The $164 million IPR&D and milestones expense negatively impacts both GAAP and adjusted non-GAAP diluted earnings per share by $0.08.
• The full-year and first quarter adjusted diluted EPS guidance ranges have been lowered to reflect this expense.

Risks

• The final results for the quarter ended March 31, 2024, are not yet finalized and may differ from these preliminary estimates.
• Future acquired IPR&D and milestone expenses are uncertain and cannot be reliably forecasted, potentially impacting future earnings.
• The company faces risks related to intellectual property, competition, research and development, litigation, and regulatory changes.

Future Outlook

AbbVie's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2024, as both cannot be reliably forecasted.

Management Comments

• AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions.
• AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Industry Context

The pharmaceutical industry often sees fluctuations in earnings due to research and development expenses, particularly those related to acquisitions and licensing agreements. This announcement reflects the inherent uncertainty in these types of investments.

Comparison to Industry Standards

• Other large pharmaceutical companies such as Pfizer, Merck, and Johnson & Johnson also experience fluctuations in earnings due to IPR&D expenses.
• These expenses are common in the industry due to the high cost of drug development and acquisitions.
• The impact of $0.08 per share is within the range of what is typically seen for similar expenses in the sector.
• It is common for companies to not forecast these expenses due to their unpredictable nature.

Stakeholder Impact

• Shareholders will see a reduction in earnings per share due to the IPR&D expense.
• Analysts may adjust their financial models to reflect the updated guidance.
• The company's financial performance will be closely monitored in the coming quarters.

Key Dates

Keywords

IPR&D, milestones, earnings per share, EPS, financial guidance, AbbVie, pharmaceuticals, adjusted earnings